|
Obesity is fast becoming a modern-day epidemic, and with direct links to diabetes and the metabolic syndrome, it has been tagged by the U.S administration a ‘public health crisis’. However, existing obesity therapeutics have failed to meet the overwhelming market demand, often accompanied by significant side-effects and demonstrating only marginal weight loss. The 2007 Targeting Obesity Conference examines the latest developments in the research of therapeutics for Obesity and related disorders: - Seeking greater efficacy in existing obesity treatments
- Successful target identification and innovative approaches
- Overcoming the challenges of adverse side-effects
The event brings together Vice Presidents, Directors, and leading Researchers from the pharmaceutical industry to share successes and discuss the critical issues surrounding the development of innovative solutions. Confirmed speakers include: - Dr Douglas Greene, Vice President, Regulatory Development, Sanofi-Aventis
- Dr Marcus Schindler, Director, Metabolic Diseases Research, Boehringer-Ingelheim
- Dr Marc Reitman, Director, Metabolic Disorders, Merck
- Dr Glenn Matfin, Head, US Medical Affairs, Novo Nordisk
- Dr Uwe Gudat, Global Brand Medical Director, Dyslipidemia and Diabetes, Novartis
- Dr Michael Trautmann, Medical Fellow, Clinical Investigation, Eli Lilly
Who Should Attend the SMi Targeting Obesity Conference? - Medical Directors
- Director of Metabolic Diseases
- Senior Scientists - Metabolic and Cardiovascular Diseases
- Directors of Clinical Research
- Senior Clinical Project Managers
Targeting Obesity Conference offers a unique opportunity to hear about the latest developments from industry leaders. Bringing together knowledge and expertise, it’s designed to create the perfect setting for the exchange of ideas and networking opportunities. For Speaking opportunities please contact Venus Simbulan at vsimbulan@smi-online.co.uk
|
Events Home Page
